SKIN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. SKIN is trading with weakening momentum (bearish MACD expansion) and no proprietary buy signals, while fundamentals in the latest quarter show shrinking revenue and deeper losses. With price sitting near key support (~1.46) and only modest upside indications, the risk/reward does not justify an immediate entry; best stance is hold/avoid new buys until momentum improves.
Price/Trend: Current price 1.495 (-1.32%) in a slightly down tape (SPX -0.23%). Momentum is soft. Indicators: MACD histogram is negative (-0.00327) and negatively expanding (bearish). RSI(6)=41.7 is neutral-to-weak (not oversold). Moving averages: Converging MAs suggests consolidation rather than a confirmed uptrend. Levels: Pivot 1.511 is overhead; resistance at 1.564 then 1.597. Support at 1.457 then 1.424. At 1.495, the stock is closer to support than resistance, but lacks a confirmed reversal signal. Pattern-based odds: Similar-pattern model suggests a 70% chance of modest gains (+2.16% next day, +2.57% next week, +8.02% next month), but these are not supported by current MACD momentum yet—more consistent with a potential bounce than a durable trend change.
leans constructive.
where short-term bounces can occur if selling pressure fades.
Bearish momentum: MACD negative and expanding indicates downside pressure isn’t finished.
Latest quarter: 2025/Q3. Revenue: 70.655M, down -10.34% YoY (top-line contraction). Profitability: Net income -11.031M (down -39.69% YoY) and EPS -0.09 (down -40.00% YoY), indicating losses deepened. Margins: Gross margin improved to 64.59% (+25.22% YoY), which is encouraging, but it has not yet translated into bottom-line improvement. Overall: Mixed quality—strong margin improvement, but deteriorating revenue and earnings trends dominate near-term fundamentals.
Recent change: TD Cowen (2026-01-21) raised price target to $1.65 from $1.50 and maintained Hold. Wall Street pros view (pros): Slightly improved outlook implied by the PT bump; broader beauty trends described as solid, which could support revenue upside. Wall Street cons view (cons): Hold rating signals limited confidence in near-term upside/visibility; PT is only modestly above the current price (~10%), suggesting capped return expectations.
